Policy Focused Sessions

• Building a World-Class Innovative Therapeutic Biologics Industry in China
BIO and R&D Based Pharmaceutical Association Committee (RDPAC) have commissioned a multi-year study on best practices in building an innovative therapeutic biologics industry in China, exploring success and failures in other markets. Key recommendations are made with the intention of providing a foundation for revision on the next five-year plan as it relates to biotechnology, one of China’s seven Strategic Emerging Industries (SEIs)
• China’s New Party Leadership, Implications for Central Planning and Regulation
This past March, China went through a historic leadership transition. As the new president, Xi Jinping, takes the helm and ministries like the China Food & Drug Administration (CFDA) are elevated in importance, what are the implications for the biotechnology industry in China?
• Looking Forward: 13th Five-Year Plan & Its Investment in Innovation
As China’s 12th Five-Year Plan concludes in 2015, the country begins to lay the groundwork for the 13th Five-Year Plan for 2016-2020. This panel will explore lessons learned, areas of strength, areas for improvement, and where industry can support central planners moving forward.